Compugen Ltd. is a clinical-stage therapeutic discovery and development company. It has immuno-oncology pipeline with multiple programs in various stages. These include COM701, COM902, Bapotulimab, Rilvegostomig, and early-stage programs. The company also has collaborations with Bayer Pharma AG, Bristol-Myers Squibb, and Johns Hopkins School of Medicine. AstraZeneca has a license agreement for bi-specific and multi-specific immuno-oncology antibody products. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 2.8 |
| ROIC | 85.8% |
| Net Debt/EBITDA | 1.1 |